Literature DB >> 7783577

Life expectancy biases in clinical decision modeling.

K M Kuntz1, M C Weinstein.   

Abstract

Clinical decision models often rely upon survival models predicated on disease-specific hazard functions combined with baseline hazard functions obtained from standard life tables. Two biases may arise in such a modeling process. First, life expectancy estimates may be biased even if estimates of survival probabilities are unbiased (misestimation bias). In simulation studies, the authors discovered that the magnitude of misestimation bias is larger as life expectancy increases, sample size decreases, and censoring percentage increases. In the context of a simple decision analysis, they found that imbalances in the sample sizes for the data used to estimate the parameters among different strategies resulted in non-optimal decisions in the long run. The second bias stems from misspecification of the survival model itself (misspecification bias). Using a simple cost-effectiveness model, the authors found that life expectancies and incremental cost-effectiveness ratios differed depending on whether an excess-mortality or a proportional-hazards model was specified. In addition, a predictable pattern was observed for these two survival models when extrapolated to other age and gender groups.

Mesh:

Year:  1995        PMID: 7783577     DOI: 10.1177/0272989X9501500209

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  8 in total

1.  Estimating future hepatitis C morbidity, mortality, and costs in the United States.

Authors:  J B Wong; G M McQuillan; J G McHutchison; T Poynard
Journal:  Am J Public Health       Date:  2000-10       Impact factor: 9.308

2.  Assessing the effectiveness of health interventions for cost-effectiveness analysis. Panel on Cost-Effectiveness in Health and Medicine.

Authors:  J S Mandelblatt; D G Fryback; M C Weinstein; L B Russell; M R Gold
Journal:  J Gen Intern Med       Date:  1997-09       Impact factor: 5.128

3.  A model-based estimate of cumulative excess mortality in survivors of childhood cancer.

Authors:  Jennifer M Yeh; Larissa Nekhlyudov; Sue J Goldie; Ann C Mertens; Lisa Diller
Journal:  Ann Intern Med       Date:  2010-04-06       Impact factor: 25.391

4.  An integrated health-economic analysis of diagnostic and therapeutic strategies in the treatment of moderate-to-severe obstructive sleep apnea.

Authors:  Jan B Pietzsch; Abigail Garner; Lauren E Cipriano; John H Linehan
Journal:  Sleep       Date:  2011-06-01       Impact factor: 5.849

5.  Validation of a decision model for preventive pharmacological strategies in postmenopausal women.

Authors:  Sylvie Perreault; Carey Levinton; Claudine Laurier; Yola Moride; Louis-Georges Ste-Marie; Ralph Crott
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

6.  Baseline mortality-adjusted survival in resected rectal cancer patients.

Authors:  Ignazio Tarantino; Sascha A Müller; Rene Warschkow; Yakup Kulu; Bruno M Schmied; Markus W Büchler; Alexis Ulrich
Journal:  J Gastrointest Surg       Date:  2014-08-05       Impact factor: 3.452

7.  Potential Bias Associated with Modeling the Effectiveness of Healthcare Interventions in Reducing Mortality Using an Overall Hazard Ratio.

Authors:  Fernando Alarid-Escudero; Karen M Kuntz
Journal:  Pharmacoeconomics       Date:  2020-03       Impact factor: 4.981

8.  Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer's disease.

Authors:  Spencer A W Lee; Luciano A Sposato; Vladimir Hachinski; Lauren E Cipriano
Journal:  Alzheimers Res Ther       Date:  2017-03-16       Impact factor: 6.982

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.